166 related articles for article (PubMed ID: 30949521)
1. Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France.
Demessine L; Peyro-Saint-Paul L; Gardner EM; Ghosn J; Parienti JJ
Open Forum Infect Dis; 2019 Mar; 6(3):ofz051. PubMed ID: 30949521
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy.
Peng AT; Huang SH; Lee HY; Wu PY; Kuo HY; Hung CC
Int J Antimicrob Agents; 2024 Feb; 63(2):107067. PubMed ID: 38141835
[TBL] [Abstract][Full Text] [Related]
3. The Challenge of Potential Drug-Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China.
Xia H; Gao L; Gong X; Zaongo SD; Zhang T; Wu H; Ma P; Huang X
Front Pharmacol; 2020; 11():800. PubMed ID: 32536872
[TBL] [Abstract][Full Text] [Related]
4. Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.
López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan Á; McAllister K; Bellón JM; Gibbons S; Balsalobre P; Pérez-Latorre L; Benedí J; Marzolini C; Aranguren-Oyarzábal A; Khoo S; Calvo-Alcántara MJ; Berenguer J
Clin Infect Dis; 2020 Jul; 71(2):353-362. PubMed ID: 31428770
[TBL] [Abstract][Full Text] [Related]
5. Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors.
Yeşilbağ Z; Şengül Eİ; Şenoğlu S; Aydın ÖA; Karaosmanoğlu HK
Curr HIV Res; 2020; 18(6):415-425. PubMed ID: 32787762
[TBL] [Abstract][Full Text] [Related]
6. Use of comedications and potential drug-drug interactions in people living with HIV in China.
Chen R; Chen J; Tang Q; Meng Z; Luo L; Zhang W; Deng A; Zhang L; Wang J; Qi T; Zhang R; Shen Y; Liu L; Steinhart C; Lu H
J Infect Chemother; 2020 Jul; 26(7):722-728. PubMed ID: 32354599
[TBL] [Abstract][Full Text] [Related]
7. High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
Cota JM; Benavides TM; Fields JD; Jansen N; Ganesan A; Colombo RE; Blaylock JM; Maves RC; Agan BK; Okulicz JF
PLoS One; 2021; 16(5):e0250607. PubMed ID: 33956843
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
Okoli C; Schwenk A; Radford M; Myland M; Taylor S; Darley A; Barnes J; Fox A; Grimson F; Reeves I; Munshi S; Croucher A; Boxall N; Benn P; Paice A; van Wyk J; Khoo S
HIV Med; 2020 Sep; 21(8):471-480. PubMed ID: 32671950
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.
Baecke C; Gyssens IC; Decoutere L; van der Hilst JCH; Messiaen P
Neth J Med; 2017 Jul; 75(6):235-240. PubMed ID: 28741582
[TBL] [Abstract][Full Text] [Related]
10. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
[TBL] [Abstract][Full Text] [Related]
11. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
[TBL] [Abstract][Full Text] [Related]
12. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-drug interaction in an elderly human immunodeficiency virus population: Comparison of 3 expert databases.
Ruellan AL; Bourneau-Martin D; Joyau C; Secher S; Fialaire P; Hitoto H; Leautez S; Michau C; Vatan R; Billaud E; Briet M; Jolliet P; Raffi F; Allavena C
Br J Clin Pharmacol; 2021 Mar; 87(3):1194-1202. PubMed ID: 32696528
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K
Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940
[TBL] [Abstract][Full Text] [Related]
15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.
Park MS; Yang YM; Kim JS; Choi EJ
Ther Clin Risk Manag; 2018; 14():2229-2241. PubMed ID: 30519031
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE).
Cheng CY; Luo YZ; Wu PY; Liu WC; Yang SP; Zhang JY; Cheng SH; Hung CC
J Int AIDS Soc; 2014; 17(4 Suppl 3):19785. PubMed ID: 25397529
[TBL] [Abstract][Full Text] [Related]
18. Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey.
Tinggaard M; David KP; Gerstoft J; Hansen AE; Kirk O; Lebech AM; Lindhardt BØ; Rose MV; Ryom L; Weis N; Benfield T
HIV Med; 2023 Jan; 24(1):46-54. PubMed ID: 35521975
[TBL] [Abstract][Full Text] [Related]
19. Potential drug-drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms.
Burger D; Oosterhof P; Grintjes K; Marneef-Pietersma M; d'Ancona F; Zhu X; Keijmel S; Richel O; van Crevel R; Jansen D
HIV Med; 2023 Oct; 24(10):1083-1087. PubMed ID: 37292046
[TBL] [Abstract][Full Text] [Related]
20. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
